Quince Therapeutics, Inc. (QNCX) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is neutral — 2 Buy, 5 Hold, 2 Sell.
Analysts estimate Earnings Per Share (EPS) of $-1.22 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.31 vs est $-1.22 (missed -7.7%). Analyst accuracy: 93%.
QNCX Analyst Ratings
Hold
Based on 9 analysts giving stock ratings to Quince Therapeutics, Inc. in the past 3 months
EPS Estimates — QNCX
93%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual –$1.31
vs Est –$1.22
▼ 7.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — QNCX
Revenue Trend
Analysts expect stable revenue going forward.
